NewsBenzingaRoswell Park e Generate Biomedicines annunciano il primo paziente trattato nel primo studio clinico sull’uomo che valuta GB-5267, una terapia CAR-T autologa sperimentale armata con IL-18. Roswell Park e Generate Biomedicines annunciano il primo paziente trattato nel primo studio clinico sull’uomo che valuta GB-5267, una terapia CAR-T autologa sperimentale armata con IL-18. Benzinga 2026.10.01 11:14 (GMT+0) Open on Benzinga Other news Israeli Shipping Giant ZIM Cashes In on Surging Freight Rates, Raises Outlook UBS Maintains Buy on Home Depot, Lowers Price Target to $417 Disney Posts Upbeat Q4, Analysts Raise Price Target Citing Theme Park Resilience StoneX Maintains Buy on Bitdeer Techs, Lowers Price Target to $15 Merck Pulls Plug On Acquired Drug after Safety Review UBS Maintains Neutral on Granite Point Mortgage Tr, Lowers Price Target to $3